A recent survey on the use of direct oral anticoagulants (DOACs) revealed that 43% of
patients with atrial fibrillation and renal impairment were potentially overdosed and had a …

Oral anticoagulant therapy (OAT) is widely used to prevent and treat thromboembolic events.
Traditionally, warfarin has been the drug of choice and, indeed, this drug is effective and …

Background Novel oral anticoagulants are approved in several indications: rivaroxaban,
apixaban, and dabigatran for the prevention of venous thromboembolism after elective hip …

Unlike traditional anticoagulants, the more recently developed agents rivaroxaban,
dabigatran and apixaban target specific factors in the coagulation cascade to attenuate …

Due to their mechanism of action, the new oral anticoagulants are named direct oral
anticoagulants (DOACs). Dabigatran is a selective, competitive, direct inhibitor of thrombin …

Anticoagulants are widely used to prevent and treat venous thromboembolism, prevent
stroke in atrial fibrillation, and manage acute coronary syndrome. These drugs are often …

Oral anticoagulation therapy is transforming with the advent of the target specific oral
anticoagulants, particularly, the direct thrombin inhibitors and factor Xa inhibitors. These …

The direct thrombin inhibitor, dabigatran, as well as the direct factor Xa inhibtors
rivaroxaban, apixaban, and edoxaban, display pharmacodynamic features quite similar to …

Dabigatran, apixaban, and rivaroxaban have been approved for primary and secondary
stroke prevention in patients with atrial fibrillation. However, questions have arisen about …

In recent years, the options for anticoagulant therapy have examined new direct oral
anticoagulants (DOACs) comprising direct thrombin inhibitors (dabigatran) and direct factor …